A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Inclusion Criteria:

• Body weight >= 40 kg at screening.

• Treated with eculizumab or ravulizumab for PNH for at least 3 months prior to Day 1.

• Lactate Dehydrogenase Levels =< 2x the upper limit of normal (ULN) at screening.

• Willingness and ability to comply with all study visits and procedures.

• Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry.

• Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years priorto initiation of study treatment; or, if not previously done, vaccinationadministered no later than one week after the first drug administration.

• Women of childbearing potential: agreement to remain abstinent (refrain fromheterosexual intercourse) or use contraception during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final doseof eculizumab (or longer if required by the local product label).

Exclusion Criteria:

• History of allogeneic bone marrow transplantation.

• History of myelodysplastic syndrome with Revised International Prognostic ScoringSystem (IPSS-R) prognostic risk categories of intermediate, high and very high.

• Pregnant or breastfeeding, or intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose ofeculizumab (or longer if required by the local product label).

• Participation in another interventional treatment study with an investigationalagent or use of any experimental therapy within 28 days of screening or within 5half-lives of that investigational product, whichever was greater: participantsenrolled in an eculizumab or ravulizumab interventional study are eligible providedthey fulfill eligibility (e.g., are willing and able to comply with the studyassessments) and stop their participation in current trial beforerandomisation/enrolment.

• Positive for Active Hepatitis B and C infection (HBV/HCV).

• Concurrent disease, treatment, procedure, or surgery or abnormality in clinicallaboratory tests that could interfere with the conduct of the study, may pose anyadditional risk for the participant, or would, in the opinion of the investigator,preclude the participant's safe participation in and completion of the study.

• History of or ongoing cryoglobulinemia at screening.